Information  X 
Enter a valid email address

Verona Pharma plc (VRP)

  Print      Mail a friend

Friday 10 August, 2018

Verona Pharma plc

Verona Pharma plc : PDMR Dealing & Issue of Shares

Verona Pharma plc : PDMR Dealing & Issue of Shares

LONDON, Aug. 10, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that, on August 9, 2018, Dr. David Ebsworth, Chairman of the Company, purchased 12,000 ordinary shares of 5 pence each in the Company (the “Ordinary Shares”) at a price of 120.00 pence per Ordinary Share.  Following the acquisition, Dr. Ebsworth will have an interest in the Company of 147,787 Ordinary Shares, representing 0.14% of the Company’s issued share capital.

The notification set out below is provided in accordance with the requirements of the EU Market Abuse Regulation.

The Company also announces that, on August 9, 2018, it issued 58,112 new Ordinary Shares (the “New Ordinary Shares”) following the vesting of restricted stock units held by a former employee, Dr. Ken Newman.  Application will be made to the London Stock Exchange for the New Ordinary Shares to be admitted to trading on AIM, with dealings expected to commence on 16 August 2018 (“Admission”). Following Admission, the Company will have a total of 105,075,513 Ordinary Shares in issue each carrying one voting right. The Company does not hold any Ordinary Shares in Treasury. This figure of 105,075,513 Ordinary Shares may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

1Details of the person discharging managerial responsibilities/person closely associated 
a)NameDavid Ebsworth 
2Reason for the notification 
a) Position/statusChairman 
b)Initial notification/AmendmentInitial notification 
3Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor  
a)NameVerona Pharma plc 
4Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted  
a)Description of the financial instrument, type of instrumentOrdinary Shares of 5 pence each 
 Identification codeGB00BYW2KH80 
b)Nature of the transactionDavid Ebsworth purchased 12,000 Ordinary Shares 
c)Price(s) and volume(s) Price(s)Volume(s) 
   120.00 pence per Ordinary Share12,000 Ordinary Shares 
d)Aggregated informationN/A  
 -  Aggregated volume    
 -  Price    
e)Date of the transaction9 August 2018 
f)Place of the transactionLondon Stock Exchange, AIM  

For further information, please contact:

Verona Pharma plcTel: +44 (0)20 3283 4200
Jan-Anders Karlsson, Chief Executive Officer[email protected]
Stifel Nicolaus Europe Limited (Nominated Adviser and UK Broker)Tel: +44 (0) 20 7710 7600
Stewart Wallace / Jonathan Senior / Ben Maddison 

a d v e r t i s e m e n t